Feasibility Study of HyperSight CBCT for Cancer Patients

This study is testing a new imaging technology called HyperSight CBCT (Cone Beam Computed Tomography) against the standard CBCT used in radiation therapy. CBCT helps doctors precisely aim radiation treatments. While standard CBCT is good for positioning, its image quality can be limited. HyperSight CBCT aims to improve image quality, making it more useful for other aspects of your radiation treatment. You may be able to join if you are at least 18 years old and receiving radiation therapy for certain cancers, including head and neck, breast, thoracic, liver, or genitourinary cancers. The study will compare the image quality of HyperSight CBCT to conventional CBCT, looking at things like image contrast and how clear the images are. The study is currently unclear on its recruitment status.

Study design
This interventional study plans to enroll 50 participants. It compares two different types of CBCT imaging technology.
What's involved
You will receive your daily radiation treatment on a system with HyperSight CBCT imaging. For 1 to 3 treatment sessions, you will receive treatment on a system with conventional CBCT imaging.
Compensation
Not stated in the trial record.
Follow-up
Image comparisons will be measured at the end of radiation treatment, at 9 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06681233

Feasibility Study of CBCT for IGRT in Cancer Patients

Recruiting
NAAges 18+Interventional
Varian, a Siemens Healthineers Company
~50 participants
Updated 2026-03-13 on ClinicalTrials.gov
What's tested:Comparison of HyperSight CBCT imaging to conventional CBCT imaging.

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Comparison of Image Contrast Resolution
Measured over End of radiation treatment at 9 weeks.
+2 more outcomes measured
Head and Neck Cancers
Breast Cancer
Thoracic Cancers
Liver Cancer
Genito Urinary Cancer
Gastrointestinal Cancers
4 sites across 1 states
Ohio4

Opens a ready-to-send draft in your own email app — review before sending.

  • Comparison of Image Contrast ResolutionEnd of radiation treatment at 9 weeks.

    The difference in contrast resolution will be evaluated between a standard CBCT image, a CBCT image acquired using HyperSight technology, and a standard fan-beam CT acquired as part of the treatment simulation and planning process

  • Comparison of Image UniformityEnd of radiation treatment at 9 weeks.

    The difference in image uniformity will be evaluated between a standard CBCT image, a CBCT image acquired using HyperSight technology, and a standard fan-beam CT acquired as part of the treatment simulation and planning process.

  • Qualitative Image ComparisonEnd of radiation treatment at 9 weeks.

    Qualitative comparison of HyperSight CBCT to conventional CBCT to determine preferred imaging for patient localization for daily treatment. Clinician observers will rank their preference using a 5-point Likert scale, where 1 represents strong preference of one imaging modality and 5 represents strong preference for the other modality.